Related Experiment Video

Updated: Jul 31, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.5K

MBD2 facilitates tumor metastasis by mitigating DDB2 expression

Lei Zhang1, Siyuan Wang2, Guo-Rao Wu1

  • 1Department of Respiratory and Critical Care Medicine, The Center for Biomedical Research, NHC Key Laboratory of Respiratory Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, 430030, Wuhan, China.

Cell Death & Disease
|May 4, 2023
PubMed

Insights

Methyl-CpG-binding domain 2 (MBD2) promotes tumor metastasis by repressing DDB2 expression. Targeting MBD2 with siRNA liposomes may offer a new therapeutic strategy for metastasis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Epigenetics

Background:

  • Tumor metastasis remains a major challenge in cancer treatment due to poorly understood underlying mechanisms.
  • The role of methyl-CpG-binding domain 2 (MBD2) in tumor metastasis is not fully elucidated, despite its known involvement in tumor development.

Purpose of the Study:

  • To investigate the role of MBD2 in tumor metastasis, particularly in lung adenocarcinoma (LUAD).
  • To explore MBD2 as a potential prognostic marker and therapeutic target for metastasis.

Main Methods:

  • Correlation analysis of MBD2 expression in LUAD metastasis patients.
  • In vitro knockdown of MBD2 in LUAD (A549, H1975) and B16F10 melanoma cells to assess migration, invasion, and epithelial-mesenchymal transition (EMT).
  • Mechanistic study involving MBD2 binding to the DDB2 promoter and in vivo therapeutic evaluation using MBD2 siRNA-loaded liposomes in B16F10 tumor-bearing mice.

Main Results:

  • Elevated MBD2 expression is significantly correlated with LUAD metastasis.
  • MBD2 knockdown suppressed LUAD and B16F10 cell migration, invasion, and EMT.
  • MBD2 was found to bind the methylated DDB2 promoter, repressing DDB2 expression and promoting metastasis.
  • MBD2 siRNA liposomes effectively inhibited EMT and attenuated tumor metastasis in vivo.

Conclusions:

  • MBD2 plays a crucial role in promoting tumor metastasis by regulating DDB2 expression.
  • MBD2 is a potential prognostic biomarker for tumor metastasis.
  • MBD2 siRNA-loaded liposomes represent a promising therapeutic strategy for combating tumor metastasis.

More Related Videos

A Protocol for Genetic Induction and Visualization of Benign and Invasive Tumors in Cephalic Complexes of Drosophila melanogaster07:23

A Protocol for Genetic Induction and Visualization of Benign and Invasive Tumors in Cephalic Complexes of Drosophila melanogaster

Published on: September 11, 2013

9.6K
Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics08:11

Characterization of Cell Membrane Extensions and Studying Their Roles in Cancer Cell Adhesion Dynamics

Published on: March 26, 2018

8.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K